2014 ASA Biopharmaceutical Section FDA-Industry Workshop

Berry Consultants will have a strong presence at the 2014 ASA Biopharmaceutical Section FDA-Industry Statistics Workshop
 on September 22-24, 2014, in Washington D.C.  Team members attending and presenting are Jason Connor, Kert Viele, and Scott Berry.  A summary of their sessions are below:

Jason Connor will be part of the Tuesday, September 23rd Roundtable Discussions from 11:45am-1:00pm, and lead the discussion on "Comparative Effectiveness in Off-Label Indications".

-Kert Viele will present "Properties of Historical Borrowing in Clinical Trials" during the Parallel Session: Bayesian Methods in Drug Developent: An Era of Synthesizing Evidence at 4:00pm-5:15pm on Tuesday, September 23rd.

-Scott Berry's presentation on "Trial Simulation for Adaptive Designs" will be on Wednesday, September 24 in the Parallel Session: Considerations and Challenges in Using Simulations for Regulatory Decision Making from 12:45pm-2:00pm. 

To attend these sessions or to see all other available sessions, please see the Online Program here.

More Recent News

February 2024 QUOTES Webinar

Berry Consultants will be hosting a webinar on the optimization of a clinical trial design by estimating its impact on the expected net present value of a drug development program using the software QUOTES (Quantification and Optimization of Trial Expectations Simulator).

Blog: Precision Promise Adaptive Platform Trial update

Blog by: Kert Viele News from the Precision Promise platform trial. https://fibrogen.gcs-web.com/news-releases/news-release-details/fibrogen-announces-completion-pamrevlumab-arm-precision-promise Precision Promise is an adaptive platform trial investigating potential therapies for pancreatic cancer,

January 2024 FACTS Webinar

The Berry Consultants software team will be hosting its January FACTS webinar next Friday, January 19th at 11am EST to present the development plans for adding an ordinal endpoint option to the trial simulator.

Blog: Comments on the draft FDA master protocol guidance

Blog by: Kert Viele The FDA draft master protocol guidance is out https://www.fda.gov/regulatory-information/search-fda-guidance-documents/master-protocols-drug-and-biological-product-development Comments are due by February 22. Here are some preliminary thoughts and